$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000154908420000016 Filed on April 30, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$1.468M	$3.616M
YoY Change	-59.4%	43.61%
Cost Of Revenue	$831.0K	$2.017M
YoY Change	-58.8%	15.19%
Gross Profit	$637.0K	$1.599M
YoY Change	-60.16%	108.47%
Gross Profit Margin	43.39%	44.22%
Selling, General & Admin	$4.707M	$5.127M
YoY Change	-8.19%	-32.46%
% of Gross Profit	738.93%	320.64%
Research & Development	$711.0K	$1.384M
YoY Change	-48.63%	-23.45%
% of Gross Profit	111.62%	86.55%
Depreciation & Amortization	$164.0K	$247.0K
YoY Change	-33.6%	-42.29%
% of Gross Profit	25.75%	15.45%
Operating Expenses	$5.418M	$6.511M
YoY Change	-16.79%	-30.59%
Operating Profit	-$4.781M	-$4.912M
YoY Change	-2.67%	-42.97%
Interest Expense	$52.00K	$121.0K
YoY Change	-57.02%	-25.77%
% of Operating Profit
Other Income/Expense, Net	$2.247M	-$1.639M
YoY Change	-237.1%	-330.2%
Pretax Income	-$2.530M	-$6.550M
YoY Change	-61.37%	-17.09%
Income Tax
% Of Pretax Income
Net Earnings	-$2.534M	-$6.551M
YoY Change	-61.32%	-17.07%
Net Earnings / Revenue	-172.62%	-181.17%
Basic Earnings Per Share
Diluted Earnings Per Share	-$436.2K	-$1.509M
COMMON SHARES
Basic Shares Outstanding	87.05M shares	64.26M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.520M	$9.240M
YoY Change	-7.79%	-55.08%
Cash & Equivalents	$8.516M	$9.236M
Short-Term Investments
Other Short-Term Assets	$410.0K	$510.0K
YoY Change	-19.61%	-46.88%
Inventory	$2.483M	$3.300M
Prepaid Expenses
Receivables	$2.658M	$3.793M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$14.06M	$16.84M
YoY Change	-16.47%	-39.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.530M	$2.331M
YoY Change	-34.36%	-0.81%
Goodwill	$189.0K	$189.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$182.0K	$140.0K
YoY Change	30.0%	16.67%
Total Long-Term Assets	$2.882M	$4.025M
YoY Change	-28.4%	33.28%
TOTAL ASSETS
Total Short-Term Assets	$14.06M	$16.84M
Total Long-Term Assets	$2.882M	$4.025M
Total Assets	$16.94M	$20.86M
YoY Change	-18.77%	-32.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.999M	$2.474M
YoY Change	-19.2%	-27.02%
Accrued Expenses	$1.716M	$3.286M
YoY Change	-47.78%	19.06%
Deferred Revenue	$1.231M	$1.211M
YoY Change	1.65%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.170M	$2.333M
YoY Change	-6.99%	0.0%
Total Short-Term Liabilities	$7.550M	$9.710M
YoY Change	-22.25%	-3.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$2.093M
YoY Change	-100.0%	-51.21%
Other Long-Term Liabilities	$45.00K	$54.00K
YoY Change	-16.67%	-97.0%
Total Long-Term Liabilities	$45.00K	$2.147M
YoY Change	-97.9%	-49.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.550M	$9.710M
Total Long-Term Liabilities	$45.00K	$2.147M
Total Liabilities	$11.72M	$16.33M
YoY Change	-28.24%	1.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$185.8M	-$177.7M
YoY Change	4.57%
Common Stock	$6.000K	$68.00K
YoY Change	-91.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.228M	$4.534M
YoY Change
Total Liabilities & Shareholders Equity	$16.94M	$20.86M
YoY Change	-18.77%	-32.62%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$2.534M	-$6.551M
YoY Change	-61.32%	-17.07%
Depreciation, Depletion And Amortization	$164.0K	$247.0K
YoY Change	-33.6%	-42.29%
Cash From Operating Activities	-$1.722M	-$5.177M
YoY Change	-66.74%	-23.25%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$7.000K
YoY Change	-100.0%	-77.42%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$7.000K
YoY Change	-100.0%	-77.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$7.305M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$589.0K	$6.769M
YoY Change	-108.7%	-1796.49%
NET CHANGE
Cash From Operating Activities	-$1.722M	-$5.177M
Cash From Investing Activities	$0.00	-$7.000K
Cash From Financing Activities	-$589.0K	$6.769M
Net Change In Cash	-$2.356M	$1.581M
YoY Change	-249.02%	-122.03%
FREE CASH FLOW
Cash From Operating Activities	-$1.722M	-$5.177M
Capital Expenditures	$0.00	$7.000K
Free Cash Flow	-$1.722M	-$5.184M
YoY Change	-66.78%	-23.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001549084
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P9M
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2020Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-37854
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Ekso Bionics Holdings, Inc.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	99-0367049
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1414 Harbour Way South
CY2020Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1201
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Richmond
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94804
CY2020Q1	dei	City Area Code CityAreaCode	510
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	984-1761
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Trading Symbol TradingSymbol	EKSO
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5843442	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8516000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10872000	USD
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	53000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	121000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2658000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5208000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	2483000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	2489000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	405000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	238000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	14062000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	18807000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1530000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1657000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	981000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1084000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	189000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	189000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	182000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	178000	USD
CY2020Q1	us-gaap	Assets Assets	16944000	USD
CY2019Q4	us-gaap	Assets Assets	21915000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1999000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1903000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1716000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1683000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1231000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1492000	USD
CY2020Q1	us-gaap	Notes Payable Current NotesPayableCurrent	2170000	USD
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2333000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	434000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	421000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7550000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7832000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1738000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1789000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	595000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	711000	USD
CY2020Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	1788000	USD
CY2019Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	4307000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	45000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	479000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	11716000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	15118000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5843000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5843000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5795000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5795000	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	190811000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	190019000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	223000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	50000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185812000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-183278000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	5228000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	6797000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16944000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21915000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1468000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3616000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	831000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2017000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	637000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	1599000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2520000	USD
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2809000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	711000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1384000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2187000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2318000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	5418000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	6511000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4781000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4912000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	52000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	121000	USD
CY2020Q1	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	2519000	USD
CY2019Q1	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-1122000	USD
CY2020Q1	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	USD
CY2019Q1	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	-257000	USD
CY2020Q1	ekso	Other Income Expense OtherIncomeExpense	-220000	USD
CY2019Q1	ekso	Other Income Expense OtherIncomeExpense	-139000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2247000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1639000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2534000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6551000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	173000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	148000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2361000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6403000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.51
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5803000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4338000	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	6797000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2534000	USD
CY2020Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	155000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	155000	USD
CY2020Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	50000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	587000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	173000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	5228000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2728000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6551000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7305000	USD
CY2019Q1	ekso	Stock Issued During Period Value Equiposis Supply And Sales Earnouts StockIssuedDuringPeriodValueEquiposisSupplyAndSalesEarnouts	22000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	55000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	191000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	636000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	148000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	4534000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2534000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6551000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	164000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	247000	USD
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	23000	USD
CY2019Q1	us-gaap	Inventory Write Down InventoryWriteDown	19000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2019Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	55000	USD
CY2020Q1	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	2519000	USD
CY2019Q1	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-1122000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	587000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	636000	USD
CY2020Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	13000	USD
CY2019Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	29000	USD
CY2020Q1	ekso	Common Stock Contribution CommonStockContribution	77000	USD
CY2019Q1	ekso	Common Stock Contribution CommonStockContribution	55000	USD
CY2020Q1	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	USD
CY2019Q1	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	-257000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-219000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-152000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2550000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	188000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	55000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	154000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	68000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	142000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	96000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-660000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	37000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-167000	USD
CY2020Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-312000	USD
CY2019Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	113000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1722000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5177000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7305000	USD
CY2020Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	589000	USD
CY2019Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	591000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	55000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-589000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6769000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-45000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2356000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1581000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10872000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7655000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8516000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9236000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	32000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	96000	USD
CY2020Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	3000	USD
CY2019Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020Q1	ekso	Operating Leases Right Of Use Asset Initial Recognition OperatingLeasesRightOfUseAssetInitialRecognition	0	USD
CY2019Q1	ekso	Operating Leases Right Of Use Asset Initial Recognition OperatingLeasesRightOfUseAssetInitialRecognition	1454000	USD
CY2020Q1	ekso	Operating Leases Liability Initial Recognition OperatingLeasesLiabilityInitialRecognition	0	USD
CY2019Q1	ekso	Operating Leases Liability Initial Recognition OperatingLeasesLiabilityInitialRecognition	1498000	USD
CY2020Q1	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	38000	USD
CY2019Q1	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	206000	USD
CY2020Q1	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	155000	USD
CY2019Q1	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	191000	USD
CY2020Q1	us-gaap	Stock Issued1 StockIssued1	50000	USD
CY2019Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020Q1	ekso	Sales Earnout SalesEarnout	0	USD
CY2019Q1	ekso	Sales Earnout SalesEarnout	22000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185812000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1722000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8516000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10872000	USD
CY2020Q1	ekso	Debt Covenant Covenant Compliance Unrestricted Cash DebtCovenantCovenantComplianceUnrestrictedCash	3565000	USD
CY2020Q1	ekso	Unrestricted Cash UnrestrictedCash	4951000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</span></div>
CY2019Q1	us-gaap	Grants Receivable GrantsReceivable	1500000	USD
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers, most of which are hospitals or other large nationally recognizable institutions, in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of March 31, 2020 and December 31, 2019.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At March 31, 2020, the Company had two customers with an accounts receivable balance totaling 10% or more of the Company’s total accounts receivable (10% and 12%), as compared with one customer at December 31, 2019 (11%).</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, the Company had one customer with sales of 10% or more of the Company’s total revenue (16%), as compared with one customer in the three months ended March 31, 2019 (11%).</span></div>
CY2020Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	20000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	29000	USD
CY2020Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2027000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2208000	USD
CY2020Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	436000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	252000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	2483000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	2489000	USD
CY2020Q1	ekso	Deferred Extended Maintenance And Support DeferredExtendedMaintenanceAndSupport	2628000	USD
CY2019Q4	ekso	Deferred Extended Maintenance And Support DeferredExtendedMaintenanceAndSupport	2837000	USD
CY2020Q1	ekso	Deferred Royalties DeferredRoyalties	285000	USD
CY2019Q4	ekso	Deferred Royalties DeferredRoyalties	290000	USD
CY2020Q1	us-gaap	Deferred Revenue Leases Net DeferredRevenueLeasesNet	44000	USD
CY2019Q4	us-gaap	Deferred Revenue Leases Net DeferredRevenueLeasesNet	131000	USD
CY2020Q1	ekso	Contract With Customers Liability Customer Deposits And Advances ContractWithCustomersLiabilityCustomerDepositsAndAdvances	12000	USD
CY2019Q4	ekso	Contract With Customers Liability Customer Deposits And Advances ContractWithCustomersLiabilityCustomerDepositsAndAdvances	23000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2969000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3281000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1231000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1492000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1738000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1789000	USD
CY2020Q1	ekso	Debt Covenant Covenant Compliance Unrestricted Cash DebtCovenantCovenantComplianceUnrestrictedCash	3565000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8516000	USD
CY2020Q1	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P12M
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2658000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5208000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3281000	USD
CY2020Q1	ekso	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	221000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	533000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2969000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2969000	USD
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	958000	USD
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	945000	USD
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1054000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1468000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3616000	USD
CY2019Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	285000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1716000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1683000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	221000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	300000	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1275000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1098000	USD
CY2020Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	220000	USD
CY2016Q4	ekso	Success Fee Expenses SuccessFeeExpenses	250000	USD
CY2016Q4	us-gaap	Share Price SharePrice	120.00
CY2020Q1	ekso	Operating Lease Base Rent OperatingLeaseBaseRent	32000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	529000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	231000	USD
CY2020Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0955
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1749000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	440000	USD
CY2020Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2189000	USD
CY2020Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	19000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	2170000	USD
CY2020Q1	ekso	Operating Leases Rent Expense Annual Incremental Percentage Increase OperatingLeasesRentExpenseAnnualIncrementalPercentageIncrease	0.03
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	387000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	138000	USD
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	140000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1147000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	118000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1029000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	434000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	595000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1029000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M8D
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5843000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5843000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1178000	shares
CY2020Q1	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	6000	shares
CY2020Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1172000	shares
CY2019Q1	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	-257000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	587000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	636000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2020Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	155000	USD
CY2020Q1	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	50000	USD
CY2020Q1	us-gaap	Contractual Obligation ContractualObligation	881000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2534000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6551000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5803000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4338000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	551000	shares
CY2020Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.51
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1847000	shares
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1468000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3616000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	45000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	2170000	USD

Files In Submission

Name	View Source	Status
0001549084-20-000016-index-headers.html	Edgar Link	pending
0001549084-20-000016-index.html	Edgar Link	pending
0001549084-20-000016.txt	Edgar Link	pending
0001549084-20-000016-xbrl.zip	Edgar Link	pending
ekso-20200331.htm	Edgar Link	pending
ekso-20200331.xsd	Edgar Link	pending
ekso-20200331_cal.xml	Edgar Link	unprocessable
ekso-20200331_def.xml	Edgar Link	unprocessable
ekso-20200331_htm.xml	Edgar Link	completed
ekso-20200331_lab.xml	Edgar Link	unprocessable
ekso-20200331_pre.xml	Edgar Link	unprocessable
ekso-3312020xex101.htm	Edgar Link	pending
ekso-3312020xex311.htm	Edgar Link	pending
ekso-3312020xex312.htm	Edgar Link	pending
ekso-3312020xex321.htm	Edgar Link	pending
ekso-3312020xex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image01.jpg	Edgar Link	pending
image11.jpg	Edgar Link	pending
image21.jpg	Edgar Link	pending
image31.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2020 Q1 Form 10-Q Financial Statement

#000154908420000016 Filed on April 30, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2020 Q1 Form 10-Q Financial Statement

#000154908420000016 Filed on April 30, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso